Reference Interval:
|
| Interpretive Data: |
Background Information for Multiple Endocrine Neoplasia Type 1 (MEN1) Deletion/Duplication:
Characteristics: Multiple Endocrine Neoplasia Type 1 (MEN1) syndrome can include multiple endocrine and non-endocrine tumors. Common MEN1-related endocrine tumors include parathyroid (90-95 percent), pancreatic islets (30-80 percent), and pituitary (15-90 percent). Non-endocrine tumors include facial angiofibroma, collagenoma, lipoma, meningioma, ependymoma, and leiomyoma. Primary hyperparathyroidism is the most common and often the first manifestation of MEN1. High mortality rates occur in persons with gastrinoma and carcinoid tumors.
Incidence: Approximately 1 in 30,000.
Inheritance: Autosomal dominant.
Penetrance: Approximately 50 percent by age 20 and 95 percent by age 40.
Cause: Pathogenic MEN1 gene mutations.
Clinical Sensitivity: Approaches 4 percent.
Methodology: Multiplex ligation-dependent probe amplification (MLPA) to detect large MEN1 coding region deletions/duplications.
Analytical Sensitivity and Specificity: Approximately 98 percent.
Limitations: Rare diagnostic errors can occur due to probe site mutations. Single base pair substitutions, small deletions/duplications, regulatory region mutations, and deep intronic mutations will not be detected. The breakpoints of large deletions/duplications will not be determined. Mutations in genes other than MEN1 are not evaluated.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.
See Compliance Statement C: www.aruplab.com/CS
|
| CPT Code(s): |
81404
|
Cross References: |
MEN1 (Multiple Endocrine Neoplasia Type 1 (MEN1) Deletion/Duplication)
|
|
![[ image for: Patient History for Multiple Endocrine Neoplasia Type 1 (MEN1) Gene Testing]](icon_81.jpg){kind=icon}
![[ image for: Additional Technical Information]](icon_315.jpg){kind=icon}